Estrella Immunopharma, Inc. (NASDAQ:ESLA – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 928,945 shares, a growth of 54.9% from the October 15th total of 599,647 shares. Based on an average daily trading volume, of 2,497,705 shares, the days-to-cover ratio is currently 0.4 days. Currently, 2.3% of the shares of the company are sold short.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Estrella Immunopharma stock. BlackRock Inc. acquired a new stake in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned approximately 0.12% of Estrella Immunopharma as of its most recent SEC filing. Hedge funds and other institutional investors own 0.35% of the company’s stock.
Analyst Ratings Changes
Separately, Weiss Ratings raised shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, October 28th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Estrella Immunopharma presently has a consensus rating of “Hold” and an average target price of $8.00.
Check Out Our Latest Analysis on ESLA
Estrella Immunopharma Price Performance
Shares of ESLA traded up $0.04 during trading hours on Wednesday, hitting $0.37. The company’s stock had a trading volume of 105,480 shares, compared to its average volume of 661,312. The company has a market cap of $16.05 million, a price-to-earnings ratio of -1.32 and a beta of 0.88. The business has a 50 day simple moving average of $0.53 and a two-hundred day simple moving average of $0.95. Estrella Immunopharma has a 52-week low of $0.24 and a 52-week high of $2.27.
Estrella Immunopharma Company Profile
Estrella Immunopharma is a clinical-stage biotechnology company developing T-cell therapies for cancer and autoimmune diseases. Its approach is designed to direct a patient’s immune cells to recognize and attack disease-associated targets. The company’s lead program, EB103, is an investigational T-cell therapy that targets CD19, a protein found on certain B cells. Estrella is developing the treatment for B-cell malignancies, including non-Hodgkin lymphoma. Its programs use the ARTEMIS platform, which was developed by Eureka Therapeutics.
Read More
- Five stocks we like better than Estrella Immunopharma
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
Receive News & Ratings for Estrella Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Estrella Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
